Safety of a 0.5mg Dose of hLF1-11 Given for 10 Consecutive Days to Autologous Haematopoietic Stem Cell Transplant Recipients.

Trial Profile

Safety of a 0.5mg Dose of hLF1-11 Given for 10 Consecutive Days to Autologous Haematopoietic Stem Cell Transplant Recipients.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Lactoferrin 1-11 (Primary)
  • Indications Bacterial infections; Mycoses
  • Focus Adverse reactions
  • Sponsors AM-Pharma
  • Most Recent Events

    • 12 Jan 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 14 Apr 2009 New source identified and integrated (Netherlands Trial Register NTR672).
    • 16 Oct 2008 Planned end date changed from 1 Sep 2008 to 1 Jun 2009, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top